NEW YORK (GenomeWeb) – Response Genetics today said that its third quarter revenues rose 9 percent year over year on higher testing revenues and volumes.

The Los Angeles-based molecular diagnostics firm reported $4.5 million in revenues for the three months ended Sept. 30, up from $4.1 million a year ago as ResponseDX sales offset lower pharmaceutical client revenue. ResponseDX revenues increased 54 percent year over year to $3.9 million, while ResponseDX volumes were up 28 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.